Status:
COMPLETED
Locobase® REPAIR Used as an Adjunctive to Standard Therapy in Children With Moderate to Severe Atopic Dermatitis
Lead Sponsor:
Astellas Pharma Europe B.V.
Conditions:
Dermatitis, Atopic
Eligibility:
All Genders
18-16 years
Phase:
PHASE4
Brief Summary
To assess the efficacy of Locobase REPAIR® when used in children with moderate to severe AD
Eligibility Criteria
Inclusion
- Has given written informed consent (parents or guardian, child if applicable)
- Moderate to severe AD
- Continuous use of topical corticosteroid or topical calcineurin inhibitor (TCI) as active treatment of AD for more than 4 weeks prior to screening (no change in topical corticosteroid or TCI is allowed between screening and day 1)
- In the opinion of the investigator, subject is unlikely to require a significant change to his/her current treatment regimen during the study period
Exclusion
- Has infected lesions
- The last assessment of any clinical study within 3 months prior to the expected date of entering into the study
- Current use of Locobase® REPAIR
- Known allergy to Locobase® REPAIR or any of its components
- Any clinical condition which, in the opinion of the investigator, would not allow safe completion of the study
Key Trial Info
Start Date :
March 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
49 Patients enrolled
Trial Details
Trial ID
NCT00673725
Start Date
March 1 2008
End Date
September 1 2008
Last Update
August 25 2014
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Liverpool, United Kingdom
2
Manchester, United Kingdom
3
Reading, United Kingdom